A Phase 2 interventional study of Octreotide LAR and Octreotide (Immediate release) in Peritoneal Neoplasms, Intestinal Obstruction and Carcinomatosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Peritoneal Neoplasms with a site in France — 8 open to participants now, 9 under way, 2 of them phase 3. Peritoneal Neoplasms · France.
Among the 40 studies in Peritoneal Neoplasms with a site in France, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 2, and was the 3rd registered.
249 studies on the registry are indexed under Peritoneal Neoplasms; 55 are open to participants now.
Browse Peritoneal Neoplasms studies →8 of the 40 studies in Peritoneal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in France, United States, Australia and 24 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Hospices Civils de Lyon · Sites in France
Ages 18+
Corcept Therapeutics · Sites in France, United States, Belgium and 5 more countries
Ages 18+ · Women only
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 49 Peritoneal Neoplasms studies recruiting now, 35 (71%) set no upper age limit and 8 (16%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 10
First in 2003; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 46 across 202 interventional studies indexed under Peritoneal Neoplasms.
Median enrollment 73 across the 32 interventional studies, 108 across the 8 observational. Of the 28 that completed or were terminated, 5 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Peritoneal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Peritoneal Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04024917Institut du Cancer de Montpellier - Val d'AurelleImpact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis | 2026-12 |
| NCT03976999Institut du Cancer de Montpellier - Val d'AurelleDevelopment of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | 2027-07 |
| NCT06351475Assistance Publique - Hôpitaux de ParisEfficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Peritoneal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Non authorized concomitant treatments :
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
Drug: Octreotide LAR · Drug: Octreotide (Immediate release) · Drug: methylprednisolone
Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
Drug: methylprednisolone · Drug: Placebo
Octreotide long-acting release (LAR) 30 mg intramuscular injection.
Also known as: Sandostatin® LAR
Immediate-release Octreotide supplied in 100 µg/mL ampules.
Also known as: Sandostatin®
methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
Physiologic saline solution
Number of Participants With Treatment Success From Day 10 to Day 13
Treatment Success was defined as: less than 2 episodes of vomiting on average per day for the 4 days prior to Day 14 \[from Day 10 to Day 13\] and no use of an Nasogastric Tube (NGT) since at least Day 10 and no use of an anticholinergic agent until Day 14. Treatment Failure is defined as: 2 or more episodes of vomiting per day on average for the 4 days prior to Day 14 or use of an NGT after Day 9 or use of an anticholinergic agent before Day 14 or withdrawal from the trial between Day 1 and Day 14 (included), whatever the cause.
Time frame: Day 10 to Day 13
Number of Participants With Treatment Success From Day 5 to Day 7
Day 7 treatment success was defined as improvement of symptoms in the previous 2 days (average number of vomiting episodes less than 2 from Day 5, no Nasogastric Tube (NGT) since Day 5 and no anticholinergic agent or withdrawal from trial).
Time frame: Day 5 to Day 7
Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14
The mean number of vomiting episodes per a 24 hour period is presented for Day 1, Day 7 and Day 14.
Time frame: Day 1, Day 7 and Day 14
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 1.
Time frame: Day 1
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 7.
Time frame: Day 7
Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 14.
Time frame: Day 14
Number of Participants With Relief From Obstruction at Day 7 and Day 14
Relief from obstruction is defined by combining restart of stools for at least the previous 3 days, less than 2 episodes of vomiting on average for the previous 4 days and the restarting of flatus (gas generated in the stomach or bowels) for at least the previous 12 hours.
Time frame: Day 7 and Day 14
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
Time frame: 1 Month
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
Time frame: Month 2
Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
Time frame: Month 3
Participant's Quality of Life Using the Edmonton Scale
The Edmonton Scale consisted of 9 items: pain, activity, nausea, depression, anxiety, fatigue, appetite, sensation of well-being and dyspnea (difficult or labored breathing). Participants rated these items on a scale of 0 to 10, with 10 being the worse.
Time frame: Day 1, Day 7, Day 14, Month 1, Month 2 and Month 3
| Milestone | Octreotide | Placebo |
|---|---|---|
| Started | 32 | 32 |
| Completed day 14 visit | 21 | 15 |
| Completed | 2 | 2 |
| Not completed | 30 | 30 |
| Withdrew: Death | 24 | 14 |
| Withdrew: Insufficient therapeutic effect | 4 | 11 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Condition does not justify treatment | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Treatment Success was defined as: less than 2 episodes of vomiting on average per day for the 4 days prior to Day 14 \[from Day 10 to Day 13\] and no use of an Nasogastric Tube (NGT) since at least Day 10 and no use of an anticholinergic agent until Day 14. Treatment Failure is defined as: 2 or more episodes of vomiting per day on average for the 4 days prior to Day 14 or use of an NGT after Day 9 or use of an anticholinergic agent before Day 14 or withdrawal from the trial between Day 1 and Day 14 (included), whatever the cause.
| Participants | Octreotide | Placebo |
|---|---|---|
| TREATMENT SUCCESS | 12 | 9 |
| Vomiting episodes <2 (per day) | 19 | 13 |
| Vomiting episodes ≥2 (per day) | 2 | 2 |
| No Nasogastric Tube since Day 10 | 14 | 13 |
| Nasogastric Tube used since Day 10 | 7 | 2 |
| No Anticholinergic agents | 18 | 11 |
| Anticholinergic agents taken | 3 | 4 |
| Premature discontinuation/missing data, failure | 11 | 17 |
Day 7 treatment success was defined as improvement of symptoms in the previous 2 days (average number of vomiting episodes less than 2 from Day 5, no Nasogastric Tube (NGT) since Day 5 and no anticholinergic agent or withdrawal from trial).
| Participants | Octreotide | Placebo |
|---|---|---|
| TREATMENT SUCCESS | 22 | 20 |
| Vomiting episodes <2 (per day) since Day 5 | 28 | 25 |
| Vomiting episodes ≥2 (per day) since Day 5 | 1 | 2 |
| No Nasogastric Tube since Day 5 | 22 | 24 |
| Nasogastric Tube used since Day 5 | 7 | 3 |
| No Anticholinergic agents | 26 | 25 |
| Anticholinergic agents taken | 3 | 2 |
| Premature discontinuation/missing data | 3 | 5 |
The mean number of vomiting episodes per a 24 hour period is presented for Day 1, Day 7 and Day 14.
| Vomiting episodes | Octreotide | Placebo |
|---|---|---|
| Day 1 | 1.2 ± 2.14 | 0.6 ± 1.85 |
| Day 7 (n=31,31) | 0.3 ± 0.64 | 0.4 ± 0.84 |
| Day 14 (n=28,27) | 0.3 ± 0.81 | 0.5 ± 2.12 |
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 1.
| Participants | Octreotide | Placebo |
|---|---|---|
| Score=0 | 16 | 13 |
| Score=1 | 1 | 2 |
| Score=2 | 7 | 9 |
| Score=3 | 8 | 8 |
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 7.
| Participants | Octreotide | Placebo |
|---|---|---|
| Score=0 | 21 | 15 |
| Score=1 | 2 | 9 |
| Score=2 | 5 | 6 |
| Score=3 | 3 | 1 |
Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 14.
| Participants | Octreotide | Placebo |
|---|---|---|
| Score=0 | 22 | 22 |
| Score=1 | 2 | 3 |
| Score=2 | 2 | 1 |
| Score=3 | 2 | 1 |
Relief from obstruction is defined by combining restart of stools for at least the previous 3 days, less than 2 episodes of vomiting on average for the previous 4 days and the restarting of flatus (gas generated in the stomach or bowels) for at least the previous 12 hours.
| Participants | Octreotide | Placebo |
|---|---|---|
| Relief from Obstruction: Day 7 | 9 | 15 |
| No Relief from Obstruction: Day 7 | 20 | 12 |
| Relief from Obstruction: Day 14 | 11 | 10 |
| No Relief from Obstruction: Day 14 | 10 | 5 |
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
| Participants | Octreotide | Placebo |
|---|---|---|
| Recurrence at Month 1 | 1 | 2 |
| No Recurrence at Month 1 | 13 | 13 |
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
| Participants | Octreotide | Placebo |
|---|---|---|
| Recurrence at Month 2 | 2 | 2 |
| No Recurrence at Month 2 | 6 | 5 |
Recurrence of bowel obstruction was confirmed by abdominal X-ray.
| Participants | Octreotide | Placebo |
|---|---|---|
| Recurrence at Month 3 | 0 | 0 |
| No Recurrence at Month 3 | 3 | 2 |
The Edmonton Scale consisted of 9 items: pain, activity, nausea, depression, anxiety, fatigue, appetite, sensation of well-being and dyspnea (difficult or labored breathing). Participants rated these items on a scale of 0 to 10, with 10 being the worse.
| Scores on a scale | Octreotide | Placebo |
|---|---|---|
| Day 1 (n=30,29) | 4.12 ± 1.174 | 4.12 ± 1.360 |
| Day 7 (n=24,26) | 4.23 ± 1.695 | 3.37 ± 1.247 |
| Day 14 (n=20,14) | 4.30 ± 1.652 | 3.85 ± 1.860 |
| Month 1 (n=11,13) | 4.18 ± 1.905 | 4.49 ± 1.820 |
| Month 2 (n=7,4) | 3.46 ± 2.339 | 3.23 ± 1.609 |
| Month 3 (n=2,2) | 0.05 ± 0.071 | 1.60 ± 0.283 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide | — | 6/32 (18.8%) | 24/32 (75%) |
| Placebo | — | 6/32 (18.8%) | 19/32 (59.4%) |
| Event | Octreotide | Placebo |
|---|---|---|
| General physical health deteriorationGeneral disorders | 1/32 | 3/32 |
| SepsisInfections and infestations | 1/32 | 2/32 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/32 | 2/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/32 | 2/32 |
| Cardiac arrestCardiac disorders | 1/32 | 0/32 |
| Abdominal painGastrointestinal disorders | 0/32 | 1/32 |
| AscitesGastrointestinal disorders | 1/32 | 0/32 |
| Intestinal obstructionGastrointestinal disorders | 0/32 | 1/32 |
| VomitingGastrointestinal disorders | 0/32 | 1/32 |
| Disease progressionGeneral disorders | 0/32 | 1/32 |
| Event | Octreotide | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 7/32 | 4/32 |
| NauseaGastrointestinal disorders | 7/32 | 2/32 |
| AstheniaGeneral disorders | 7/32 | 3/32 |
| Disease progressionGeneral disorders | 7/32 | 2/32 |
| VomitingGastrointestinal disorders | 6/32 | 5/32 |
| DiarrhoeaGastrointestinal disorders | 5/32 | 3/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/32 | 3/32 |
| HyponatraemiaMetabolism and nutrition disorders | 4/32 | 0/32 |
| AnxietyPsychiatric disorders | 3/32 | 4/32 |
| Confusional statePsychiatric disorders | 4/32 | 2/32 |
| Age Continuous(years) | Octreotide | Placebo | Total |
|---|---|---|---|
| Mean | 65.3 ± 9.57 | 63.1 ± 12.36 | 64.2 ± 11.02 |
| Sex: Female, Male(Participants) | Octreotide | Placebo | Total |
|---|---|---|---|
| Female | 25 | 21 | 46 |
| Male | 7 | 11 | 18 |
The record gives a start of Sep 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide